The complex genetic architecture of Alzheimer's disease: novel insights and future directions
Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge...
Saved in:
| Published in | EBioMedicine Vol. 90; p. 104511 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.04.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations.
Two new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563—with an effective sample size of 332,376—by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD.
While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. |
|---|---|
| AbstractList | Background: Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations. Recent developments: Two new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563—with an effective sample size of 332,376—by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. Where next?: While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations. Two new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563—with an effective sample size of 332,376—by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations. Two new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563-with an effective sample size of 332,376-by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. WHERE NEXT?: While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. SummaryBackgroundAlzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations. Recent developmentsTwo new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563—with an effective sample size of 332,376—by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. Where next?While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations.BACKGROUNDAlzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability estimates of ∼70% from twin studies. Progressively larger genome-wide association studies (GWAS) have continued to expand our knowledge of AD/dementia genetic architecture. Until recently these efforts had identified 39 disease susceptibility loci in European ancestry populations.Two new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563-with an effective sample size of 332,376-by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. WHERE NEXT?: While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture.RECENT DEVELOPMENTSTwo new AD/dementia GWAS have dramatically expanded the sample sizes and the number of disease susceptibility loci. The first increased total sample size to 1,126,563-with an effective sample size of 332,376-by predominantly including new biobank and population-based dementia datasets. The second, expands on an earlier GWAS from the International Genomics of Alzheimer's Project (IGAP) by increasing the number of clinically-defined AD cases/controls in addition to incorporating biobank dementia datasets, resulting in a total sample size to 788,989 and an effective sample size of 382,472. Collectively both GWAS identified 90 independent variants across 75 AD/dementia susceptibility loci, including 42 novel loci. Pathway analyses indicate the susceptibility loci are enriched for genes involved in amyloid plaque and neurofibrillary tangle formation, cholesterol metabolism, endocytosis/phagocytosis, and the innate immune system. Gene prioritization efforts for the novel loci identified 62 candidate causal genes. Many of the candidate genes from known and newly discovered loci play key roles in macrophages and highlight phagocytic clearance of cholesterol-rich brain tissue debris by microglia (efferocytosis) as a core pathogenetic hub and putative therapeutic target for AD. WHERE NEXT?: While GWAS in European ancestry populations have substantially enhanced our understanding of AD genetic architecture, heritability estimates from population based GWAS cohorts are markedly smaller than those from twin studies. While this missing heritability is likely due to a combination of factors, it highlights that our understanding of AD genetic architecture and genetic risk mechanisms remains incomplete. These knowledge gaps result from several underexplored areas in AD research. First, rare variants remain understudied due to methodological issues in identifying them and the cost of generating sufficiently powered whole exome/genome sequencing datasets. Second, sample sizes of non-European ancestry populations in AD GWAS remain small. Third, GWAS of AD neuroimaging and cerebrospinal fluid endophenotypes remains limited due to low compliance and high costs associated with measuring amyloid-β and tau levels and other disease-relevant biomarkers. Studies generating sequencing data, including diverse populations, and incorporating blood-based AD biomarkers are set to substantially improve our knowledge of AD genetic architecture. |
| ArticleNumber | 104511 |
| Author | Andrews, Shea J. Goate, Alison M. Renton, Alan E. Fulton-Howard, Brian Marcora, Edoardo Podlesny-Drabiniok, Anna |
| Author_xml | – sequence: 1 givenname: Shea J. orcidid: 0000-0002-1921-9470 surname: Andrews fullname: Andrews, Shea J. email: shea.andrews@ucsf.edu organization: Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA – sequence: 2 givenname: Alan E. surname: Renton fullname: Renton, Alan E. organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA – sequence: 3 givenname: Brian surname: Fulton-Howard fullname: Fulton-Howard, Brian organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA – sequence: 4 givenname: Anna orcidid: 0000-0001-5009-2263 surname: Podlesny-Drabiniok fullname: Podlesny-Drabiniok, Anna organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA – sequence: 5 givenname: Edoardo surname: Marcora fullname: Marcora, Edoardo organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA – sequence: 6 givenname: Alison M. surname: Goate fullname: Goate, Alison M. organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36907103$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktv1DAUhSNURB_0FyCh7GAzg19JbBCgquJRqRILyhJZjnMz8eDYg52MaH89zqRUbSU0K1vX9zvX9jnH2YHzDrLsBUZLjHD5Zr2E2vh-SRChqcIKjJ9kR4QWZEFFyQ7u7Q-z0xjXCCFcsFTkz7JDWgpUYUSPsp9XHeTa9xsLf_IVOBiMzlXQnRlAD2OA3Lf5mb3pwPQQXsW8MRFUhLe581uwuXHRrLoh5so1eTvuiMaExBrv4vPsaatshNPb9ST78fnT1fnXxeW3LxfnZ5cLXTCOF1rpmpeMM6QrDoI0iiEQtGkpaF7ROm11RTlvhNAMkaolgIkGoSoMAKWiJ9nFrNt4tZabYHoVrqVXRu4KPqykCullFmQS46plLRKtYKQhqqywgLIVqG4IrUnS-jhrbca6h0aDG4KyD0QfnjjTyZXfSowQYZizpPD6ViH43yPEQfYmarBWOfBjlKTiZZHMqFBqfXl_2N2UfwalBjo36OBjDNDetWAkpyTItdwlQU5JkHMSEiUeUdoMarIk3djYPez7mYVk2NZAkFEbcBpmW9OPmj38h0e8tsYZrewvuIa49mNwKQsSy0gkkt-nnE4xJTRFtConA979X2Dv-L-lnfkf |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2024_112800 crossref_primary_10_1016_j_isci_2024_110256 crossref_primary_10_3390_ijms25042320 crossref_primary_10_3233_JAD_230689 crossref_primary_10_1088_2632_2153_ad829d crossref_primary_10_1093_cvr_cvae235 crossref_primary_10_3390_biom14111366 crossref_primary_10_1186_s12864_024_10363_6 crossref_primary_10_3390_brainsci14090908 crossref_primary_10_3390_ijms252211959 crossref_primary_10_1097_MD_0000000000040551 crossref_primary_10_3390_jcm13144202 crossref_primary_10_1186_s40035_025_00471_y crossref_primary_10_1016_j_xgen_2024_100555 crossref_primary_10_1093_gerona_glae270 crossref_primary_10_1001_jamaneurol_2024_2843 crossref_primary_10_1002_alz_14592 crossref_primary_10_1590_1414_431x2024e13587 crossref_primary_10_1038_s41598_024_71402_6 crossref_primary_10_1038_s41598_025_90277_9 crossref_primary_10_1016_j_jneuroim_2024_578342 crossref_primary_10_1080_07391102_2023_2294173 crossref_primary_10_1177_13872877241313049 crossref_primary_10_3390_biomedicines13010084 crossref_primary_10_1007_s11357_023_00982_4 crossref_primary_10_1038_s41467_024_52025_x crossref_primary_10_1002_alz_13796 crossref_primary_10_7554_eLife_90633 crossref_primary_10_1038_s41380_025_02925_1 crossref_primary_10_1038_s41593_025_01873_x crossref_primary_10_1093_g3journal_jkae116 crossref_primary_10_3390_ijms241713033 crossref_primary_10_1038_s41392_024_01911_3 crossref_primary_10_1093_braincomms_fcaf099 crossref_primary_10_3390_ijms25136901 crossref_primary_10_1523_JNEUROSCI_2324_22_2023 crossref_primary_10_3390_jcm13020536 crossref_primary_10_1002_alz_14208 crossref_primary_10_1016_j_phymed_2023_155150 crossref_primary_10_1080_1061186X_2024_2386620 crossref_primary_10_3390_cells13171426 crossref_primary_10_1093_bib_bbae140 crossref_primary_10_5937_mp75_54670 crossref_primary_10_1016_j_immuni_2024_03_010 crossref_primary_10_1007_s00439_024_02710_0 crossref_primary_10_1111_jnc_16002 crossref_primary_10_3389_fncel_2023_1238149 crossref_primary_10_1002_trc2_12462 crossref_primary_10_1111_acel_13938 crossref_primary_10_1186_s13073_025_01444_6 crossref_primary_10_14336_AD_2024_0322 crossref_primary_10_1016_j_ajhg_2023_12_015 crossref_primary_10_3389_fnagi_2023_1259012 crossref_primary_10_1038_s41584_024_01086_9 crossref_primary_10_3389_fnagi_2023_1290657 crossref_primary_10_1186_s12864_025_11362_x crossref_primary_10_3389_fimmu_2024_1333666 crossref_primary_10_1002_alz_13805 crossref_primary_10_3389_fneur_2024_1326692 crossref_primary_10_1007_s00415_024_12314_3 crossref_primary_10_1080_17425255_2024_2433626 crossref_primary_10_1101_lm_053816_123 crossref_primary_10_3390_biomedicines13030739 crossref_primary_10_1007_s11033_023_08674_0 crossref_primary_10_1016_j_sbi_2024_102776 crossref_primary_10_1126_sciadv_adn1927 crossref_primary_10_26508_lsa_202403080 crossref_primary_10_3390_ijms25094925 crossref_primary_10_3390_life15010096 crossref_primary_10_1016_j_biopsych_2024_11_007 crossref_primary_10_1021_acschemneuro_4c00360 crossref_primary_10_1523_JNEUROSCI_2347_23_2024 crossref_primary_10_1016_j_cbi_2023_110783 crossref_primary_10_1016_j_cmet_2024_05_017 crossref_primary_10_1186_s12974_025_03415_5 crossref_primary_10_1016_j_ebiom_2024_105238 crossref_primary_10_18632_aging_206171 crossref_primary_10_3390_ijms252212448 crossref_primary_10_1016_j_brainres_2023_148681 crossref_primary_10_1002_alz_14444 crossref_primary_10_1177_13872877241284213 crossref_primary_10_1002_alz_13753 crossref_primary_10_3892_etm_2024_12581 crossref_primary_10_1212_NXG_0000000000200224 crossref_primary_10_1186_s13024_024_00723_x crossref_primary_10_3390_ijms26062443 crossref_primary_10_1007_s11064_024_04253_2 crossref_primary_10_1093_braincomms_fcae432 crossref_primary_10_1002_alz_70031 crossref_primary_10_1186_s40035_024_00438_5 crossref_primary_10_1007_s11306_024_02193_0 crossref_primary_10_1039_D3MD00096F crossref_primary_10_3390_life14030346 crossref_primary_10_1002_ajmg_b_33019 crossref_primary_10_1016_j_celrep_2024_114061 crossref_primary_10_1590_1414_431x2024e14094 crossref_primary_10_3390_cells13141207 crossref_primary_10_1186_s40478_025_01968_3 crossref_primary_10_1007_s40847_024_00411_y crossref_primary_10_1007_s40615_024_01907_3 crossref_primary_10_3390_genes14071322 crossref_primary_10_1093_g3journal_jkad132 crossref_primary_10_3390_neurolint15030053 crossref_primary_10_1016_j_ebiom_2025_105557 crossref_primary_10_1093_ndt_gfae229 crossref_primary_10_1007_s00415_024_12673_x crossref_primary_10_1016_j_phymed_2024_155822 crossref_primary_10_1146_annurev_immunol_101921_035222 crossref_primary_10_1159_000538376 crossref_primary_10_1159_000538251 crossref_primary_10_3389_fnagi_2023_1352988 crossref_primary_10_1016_j_neuron_2024_04_009 crossref_primary_10_1038_s41577_024_01104_7 crossref_primary_10_1080_17460441_2024_2335210 crossref_primary_10_1177_13872877251316122 crossref_primary_10_1002_alz_14300 crossref_primary_10_1016_j_nbd_2023_106174 crossref_primary_10_3233_ADR_240107 crossref_primary_10_1016_j_tice_2024_102476 crossref_primary_10_1002_alz_14381 crossref_primary_10_1016_j_cjca_2024_03_025 crossref_primary_10_1021_acschemneuro_4c00472 crossref_primary_10_3390_biomedicines11082240 crossref_primary_10_1021_acschemneuro_4c00510 crossref_primary_10_1038_s41398_024_03019_2 crossref_primary_10_1212_CON_0000000000001505 |
| Cites_doi | 10.1038/s42003-022-03287-y 10.1038/s41467-019-14279-8 10.1016/j.neuron.2022.10.015 10.1038/s41380-018-0246-7 10.1186/s13024-021-00505-9 10.1016/S1474-4422(19)30435-1 10.1038/s41593-022-01031-7 10.1002/alz.12333 10.1038/s41467-021-21823-y 10.1038/s41588-021-00997-7 10.1016/j.neurobiolaging.2020.09.014 10.1038/s41588-020-00776-w 10.1038/s41588-022-01024-z 10.1038/s41588-019-0358-2 10.1038/s41588-022-01200-1 10.1126/scitranslmed.abc9375 10.1038/s41467-021-24082-z 10.1038/s41588-022-01149-1 10.1093/braincomms/fcac125 10.1186/s13059-022-02697-9 10.1038/s41588-020-0580-y 10.1186/s40478-021-01154-1 10.1038/s41380-022-01890-3 10.1038/s41588-020-00740-8 10.1093/genetics/iyaa046 10.1038/s41467-021-22491-8 10.1093/brain/awaa209 10.1186/s13024-021-00436-5 10.1038/s41588-021-00921-z 10.1186/s13024-022-00577-1 10.1038/s41588-021-00976-y 10.1038/s41588-022-01054-7 10.1016/j.cell.2022.05.017 10.1093/braincomms/fcab308 10.1038/nature11283 10.1038/s41586-020-2777-8 10.1002/alz.12534 10.1038/s41588-020-00757-z 10.1038/s41596-020-0353-1 10.1038/s41586-022-05439-w 10.1001/jamaneurol.2020.3536 10.1001/jamaneurol.2022.1166 10.1038/s41398-021-01272-3 10.1016/j.biopsych.2022.05.029 10.1038/s41588-018-0311-9 10.1002/gepi.22492 10.1038/s43586-021-00056-9 10.1038/s41588-021-00901-3 10.3389/fimmu.2020.00506 10.1371/journal.pgen.1010208 10.1126/science.abm7530 10.1007/s00401-022-02454-z |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s) The Author(s) Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. 2023 The Author(s) 2023 |
| Copyright_xml | – notice: 2023 The Author(s) – notice: The Author(s) – notice: Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. – notice: 2023 The Author(s) 2023 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ebiom.2023.104511 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3964 |
| EndPage | 104511 |
| ExternalDocumentID | oai_doaj_org_article_b938af4f09f942d2a6719e6f90bd23b2 PMC10024184 36907103 10_1016_j_ebiom_2023_104511 S2352396423000762 1_s2_0_S2352396423000762 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NIA NIH HHS grantid: U19 AG069701 – fundername: NIA NIH HHS grantid: U01 AG058635 – fundername: NIA NIH HHS grantid: R00 AG070109 – fundername: NIA NIH HHS grantid: U24 AG021886 – fundername: NIA NIH HHS grantid: P30 AG066514 |
| GroupedDBID | .1- .FO 0R~ 4.4 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAMRU AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ KQ8 M41 M48 O9- OK1 RIG ROL RPM SSZ Z5R 0SF 6I. AACTN AAFTH AFCTW NCXOZ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5481-cacb864840c78e92da40e93df3ec873b93dc7388d99c4027f2e12ce9a71eee6a3 |
| IEDL.DBID | M48 |
| ISSN | 2352-3964 |
| IngestDate | Wed Aug 27 01:22:15 EDT 2025 Thu Aug 21 18:37:30 EDT 2025 Thu Jul 10 21:13:49 EDT 2025 Wed Jul 23 01:46:08 EDT 2025 Tue Jul 01 00:39:06 EDT 2025 Thu Apr 24 23:04:09 EDT 2025 Tue Jul 25 20:56:41 EDT 2023 Sun Feb 23 10:19:34 EST 2025 Tue Aug 26 16:33:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Genome-wide association study Alzheimer's disease Review |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5481-cacb864840c78e92da40e93df3ec873b93dc7388d99c4027f2e12ce9a71eee6a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-1921-9470 0000-0001-5009-2263 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.ebiom.2023.104511 |
| PMID | 36907103 |
| PQID | 2786515470 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b938af4f09f942d2a6719e6f90bd23b2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10024184 proquest_miscellaneous_2786515470 pubmed_primary_36907103 crossref_primary_10_1016_j_ebiom_2023_104511 crossref_citationtrail_10_1016_j_ebiom_2023_104511 elsevier_sciencedirect_doi_10_1016_j_ebiom_2023_104511 elsevier_clinicalkeyesjournals_1_s2_0_S2352396423000762 elsevier_clinicalkey_doi_10_1016_j_ebiom_2023_104511 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-01 |
| PublicationDateYYYYMMDD | 2023-04-01 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | EBioMedicine |
| PublicationTitleAlternate | EBioMedicine |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Pergola, Penzel, Sportelli, Bertolino (bib49) 2022; S0006-3223 Vialle, de Paiva Lopes, Bennett, Crary, Raj (bib32) 2022; 25 Kosoy, Fullard, Zeng (bib10) 2022; 54 O'Connor (bib26) 2021; 53 Mars, Kerminen, Feng (bib48) 2022; 2 Escott-Price, Hardy (bib23) 2022; 4 Damotte, Lee, Chouraki (bib42) 2021; 17 Barry, Walker, Cheesman, Smith, Morris, Davies (bib56) 2022 Holland, Frei, Desikan (bib25) 2021; 217 Márquez-Ropero, Benito, Plaza-Zabala, Sierra (bib13) 2020; 11 Kunkle, Schmidt, Klein (bib35) 2021; 78 Grotzinger, de la Fuente, Privé, Nivard, Tucker-Drob (bib22) 2022; 93 Tcw, Qian, Pipalia (bib18) 2022; 185 Leonenko, Baker, Stevenson-Hoare (bib46) 2021; 12 Caliebe, Tekola-Ayele, Darst (bib34) 2022; 46 Amariuta, Ishigaki, Sugishita (bib51) 2020; 52 Shigemizu, Mitsumori, Akiyama (bib37) 2021; 11 Nuytemans, Vasquez, Wang (bib39) 2022; 18 Ruan, Lin, Feng (bib53) 2022; 54 Schwartzentruber, Cooper, Liu (bib3) 2021; 53 Romero-Molina, Garretti, Andrews, Marcora, Goate (bib12) 2022; 110 Armstrong, Tanigawa, Amar (bib50) 2021; 53 Fulton-Howard, Goate, Adelson (bib47) 2021; 99 de la Fuente, Grotzinger, Marioni, Nivard, Tucker-Drob (bib24) 2022; 18 Novikova, Kapoor, Tcw (bib9) 2021; 12 Liu, Murray, Li (bib31) 2021; 13 Reiman, Arboleda-Velasquez, Quiroz (bib1) 2020; 11 Lopes, Snijders, Humphrey (bib11) 2022; 54 Magno, Bunney, Mead, Svensson, Bictash (bib14) 2021; 16 Sherva, Zhang, Sahelijo (bib36) 2022; 28 Wang, Wang, Jeevaratnam (bib15) 2022; 17 Dumitrescu, Mahoney, Mukherjee (bib54) 2020; 143 Khani, Gibbons, Bras, Guerreiro (bib29) 2022; 17 Wainschtein, Jain, Zheng (bib27) 2022; 54 de Rojas, Moreno-Grau, Tesi (bib4) 2021; 12 Bellenguez, Küçükali, Jansen (bib5) 2022; 54 Jonsson, Atwal, Steinberg (bib16) 2012; 488 Mills, Rahal (bib33) 2020; 52 Jansen, van der Lee, Gomez-Fonseca (bib40) 2022; 144 Andrews, Fulton-Howard, Goate (bib2) 2020; 19 Badimon, Strasburger, Ayata (bib17) 2020; 586 Uffelmann, Huang, Munung (bib28) 2021; 1 Wightman, Jansen, Savage (bib6) 2021; 53 Blanchard, Akay, Davila-Velderrain (bib19) 2022; 611 Palmqvist, Stomrud, Cullen (bib44) 2022; 76 Dornbos, Koesterer, Ruttenburg (bib52) 2022; 54 Lewis, Molina, Appelbaum (bib38) 2022; 376 Ramanan, Lesnick, Przybelski (bib55) 2021; 9 Choi, Mak, O'Reilly (bib45) 2020; 15 Karlsson, Escott-Price, Gatz (bib21) 2022; 4 Kunkle, Grenier-Boley, Sims (bib8) 2019; 51 Sarnowski, Ghanbari, Bis (bib43) 2022; 5 Yan, Nho, Del-Aguila (bib41) 2021; 26 Jansen, Savage, Watanabe (bib7) 2019; 51 Guen, Belloy, Grenier-Boley (bib30) 2022; 79 Brandes, Weissbrod, Linial (bib20) 2022; 23 Romero-Molina (10.1016/j.ebiom.2023.104511_bib12) 2022; 110 Jansen (10.1016/j.ebiom.2023.104511_bib40) 2022; 144 Bellenguez (10.1016/j.ebiom.2023.104511_bib5) 2022; 54 Fulton-Howard (10.1016/j.ebiom.2023.104511_bib47) 2021; 99 Reiman (10.1016/j.ebiom.2023.104511_bib1) 2020; 11 Lopes (10.1016/j.ebiom.2023.104511_bib11) 2022; 54 Escott-Price (10.1016/j.ebiom.2023.104511_bib23) 2022; 4 Leonenko (10.1016/j.ebiom.2023.104511_bib46) 2021; 12 de Rojas (10.1016/j.ebiom.2023.104511_bib4) 2021; 12 Holland (10.1016/j.ebiom.2023.104511_bib25) 2021; 217 Jonsson (10.1016/j.ebiom.2023.104511_bib16) 2012; 488 Karlsson (10.1016/j.ebiom.2023.104511_bib21) 2022; 4 Palmqvist (10.1016/j.ebiom.2023.104511_bib44) 2022; 76 Dumitrescu (10.1016/j.ebiom.2023.104511_bib54) 2020; 143 Novikova (10.1016/j.ebiom.2023.104511_bib9) 2021; 12 Wang (10.1016/j.ebiom.2023.104511_bib15) 2022; 17 Damotte (10.1016/j.ebiom.2023.104511_bib42) 2021; 17 Guen (10.1016/j.ebiom.2023.104511_bib30) 2022; 79 Sherva (10.1016/j.ebiom.2023.104511_bib36) 2022; 28 Wightman (10.1016/j.ebiom.2023.104511_bib6) 2021; 53 Kunkle (10.1016/j.ebiom.2023.104511_bib8) 2019; 51 Pergola (10.1016/j.ebiom.2023.104511_bib49) 2022; S0006-3223 Khani (10.1016/j.ebiom.2023.104511_bib29) 2022; 17 Márquez-Ropero (10.1016/j.ebiom.2023.104511_bib13) 2020; 11 Caliebe (10.1016/j.ebiom.2023.104511_bib34) 2022; 46 Tcw (10.1016/j.ebiom.2023.104511_bib18) 2022; 185 Shigemizu (10.1016/j.ebiom.2023.104511_bib37) 2021; 11 Yan (10.1016/j.ebiom.2023.104511_bib41) 2021; 26 de la Fuente (10.1016/j.ebiom.2023.104511_bib24) 2022; 18 Amariuta (10.1016/j.ebiom.2023.104511_bib51) 2020; 52 Magno (10.1016/j.ebiom.2023.104511_bib14) 2021; 16 Grotzinger (10.1016/j.ebiom.2023.104511_bib22) 2022; 93 Dornbos (10.1016/j.ebiom.2023.104511_bib52) 2022; 54 Schwartzentruber (10.1016/j.ebiom.2023.104511_bib3) 2021; 53 Nuytemans (10.1016/j.ebiom.2023.104511_bib39) 2022; 18 Armstrong (10.1016/j.ebiom.2023.104511_bib50) 2021; 53 Choi (10.1016/j.ebiom.2023.104511_bib45) 2020; 15 Wainschtein (10.1016/j.ebiom.2023.104511_bib27) 2022; 54 Vialle (10.1016/j.ebiom.2023.104511_bib32) 2022; 25 Kosoy (10.1016/j.ebiom.2023.104511_bib10) 2022; 54 Uffelmann (10.1016/j.ebiom.2023.104511_bib28) 2021; 1 Liu (10.1016/j.ebiom.2023.104511_bib31) 2021; 13 Kunkle (10.1016/j.ebiom.2023.104511_bib35) 2021; 78 Barry (10.1016/j.ebiom.2023.104511_bib56) 2022 Sarnowski (10.1016/j.ebiom.2023.104511_bib43) 2022; 5 Ruan (10.1016/j.ebiom.2023.104511_bib53) 2022; 54 O'Connor (10.1016/j.ebiom.2023.104511_bib26) 2021; 53 Mars (10.1016/j.ebiom.2023.104511_bib48) 2022; 2 Jansen (10.1016/j.ebiom.2023.104511_bib7) 2019; 51 Mills (10.1016/j.ebiom.2023.104511_bib33) 2020; 52 Ramanan (10.1016/j.ebiom.2023.104511_bib55) 2021; 9 Brandes (10.1016/j.ebiom.2023.104511_bib20) 2022; 23 Andrews (10.1016/j.ebiom.2023.104511_bib2) 2020; 19 Blanchard (10.1016/j.ebiom.2023.104511_bib19) 2022; 611 Badimon (10.1016/j.ebiom.2023.104511_bib17) 2020; 586 Lewis (10.1016/j.ebiom.2023.104511_bib38) 2022; 376 |
| References_xml | – volume: 9 start-page: 48 year: 2021 ident: bib55 article-title: Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology publication-title: Acta Neuropathol Commun – volume: 12 start-page: 1610 year: 2021 ident: bib9 article-title: Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes publication-title: Nat Commun – volume: 52 start-page: 242 year: 2020 end-page: 243 ident: bib33 article-title: The GWAS Diversity Monitor tracks diversity by disease in real time publication-title: Nat Genet – volume: 11 start-page: 506 year: 2020 ident: bib13 article-title: Microglial corpse clearance: lessons from macrophages publication-title: Front Immunol – volume: 26 start-page: 309 year: 2021 end-page: 321 ident: bib41 article-title: Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging publication-title: Mol Psychiatr – volume: 17 start-page: 3 year: 2022 ident: bib29 article-title: Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease publication-title: Mol Neurodegener – volume: 17 start-page: 1663 year: 2021 end-page: 1674 ident: bib42 article-title: Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: a genome-wide association study in over 12,000 non-demented participants publication-title: Alzheimers Dementia – volume: 93 start-page: 29 year: 2022 ident: bib22 article-title: Pervasive downward bias in estimates of liability-scale heritability in GWAS meta-analysis: a simple solution publication-title: Biol Psychiatry – volume: 1 start-page: 59 year: 2021 ident: bib28 article-title: Genome-wide association studies publication-title: Nat Rev Methods Primers – volume: 217 year: 2021 ident: bib25 article-title: The genetic architecture of human complex phenotypes is modulated by linkage disequilibrium and heterozygosity publication-title: Genetics – volume: 4 start-page: fcab308 year: 2022 ident: bib21 article-title: Measuring heritable contributions to Alzheimer's disease: polygenic risk score analysis with twins publication-title: Brain Commun – volume: 16 start-page: 22 year: 2021 ident: bib14 article-title: TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation publication-title: Mol Neurodegener – volume: 611 start-page: 1 year: 2022 end-page: 11 ident: bib19 article-title: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes publication-title: Nature – volume: 488 start-page: 96 year: 2012 end-page: 99 ident: bib16 article-title: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline publication-title: Nature – volume: 54 start-page: 573 year: 2022 end-page: 580 ident: bib53 article-title: Improving polygenic prediction in ancestrally diverse populations publication-title: Nat Genet – volume: 51 start-page: 414 year: 2019 end-page: 430 ident: bib8 article-title: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing publication-title: Nat Genet – volume: 54 start-page: 1609 year: 2022 end-page: 1614 ident: bib52 article-title: A combined polygenic score of 21,293 rare and 22 common variants improves diabetes diagnosis based on hemoglobin A1C levels publication-title: Nat Genet – volume: 11 start-page: 151 year: 2021 ident: bib37 article-title: Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk publication-title: Transl Psychiatry – volume: 54 start-page: 412 year: 2022 end-page: 436 ident: bib5 article-title: New insights into the genetic etiology of Alzheimer's disease and related dementias publication-title: Nat Genet – volume: 144 start-page: 821 year: 2022 end-page: 842 ident: bib40 article-title: Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers publication-title: Acta Neuropathol – volume: 376 start-page: 250 year: 2022 end-page: 252 ident: bib38 article-title: Getting genetic ancestry right for science and society publication-title: Science – volume: 25 start-page: 504 year: 2022 end-page: 514 ident: bib32 article-title: Integrating whole-genome sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the human brain publication-title: Nat Neurosci – volume: 18 start-page: 1930 year: 2022 end-page: 1942 ident: bib39 article-title: Identifying differential regulatory control of APOE ϵ4 on African versus European haplotypes as potential therapeutic targets publication-title: Alzheimers Dementia – volume: 28 start-page: 1293 year: 2022 end-page: 1302 ident: bib36 article-title: African ancestry GWAS of dementia in a large military cohort identifies significant risk loci publication-title: Mol Psychiatry – volume: 185 start-page: 2213 year: 2022 end-page: 2233.e25 ident: bib18 article-title: Cholesterol and matrisome pathways dysregulated in astrocytes and microglia publication-title: Cell – volume: 15 start-page: 2759 year: 2020 end-page: 2772 ident: bib45 article-title: Tutorial: a guide to performing polygenic risk score analyses publication-title: Nat Protoc – year: 2022 ident: bib56 article-title: How to estimate heritability: a guide for genetic epidemiologists publication-title: Int J Epidemiol – volume: 23 start-page: 131 year: 2022 ident: bib20 article-title: Open problems in human trait genetics publication-title: Genome Biol – volume: 13 year: 2021 ident: bib31 article-title: APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia publication-title: Sci Transl Med – volume: 53 start-page: 185 year: 2021 end-page: 194 ident: bib50 article-title: Genetics of 35 blood and urine biomarkers in the UK Biobank publication-title: Nat Genet – volume: 51 start-page: 404 year: 2019 end-page: 413 ident: bib7 article-title: Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk publication-title: Nat Genet – volume: 54 start-page: 263 year: 2022 end-page: 273 ident: bib27 article-title: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data publication-title: Nat Genet – volume: 76 start-page: 1060 year: 2022 end-page: 1069 ident: bib44 article-title: An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease publication-title: Alzheimers Dementia – volume: 4 start-page: fcac125 year: 2022 ident: bib23 article-title: Genome-wide association studies for Alzheimer's disease: bigger is not always better publication-title: Brain Commun – volume: 19 start-page: 326 year: 2020 end-page: 335 ident: bib2 article-title: Interpretation of risk loci from genome-wide association studies of Alzheimer's disease publication-title: Lancet Neurol – volume: 12 start-page: 3417 year: 2021 ident: bib4 article-title: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores publication-title: Nat Commun – volume: 110 start-page: 3513 year: 2022 end-page: 3533 ident: bib12 article-title: Microglial efferocytosis: diving into the Alzheimer's disease gene pool publication-title: Neuron – volume: 99 start-page: 101.e1 year: 2021 end-page: 101.e9 ident: bib47 article-title: Greater effect of polygenic risk score for Alzheimer's disease among younger cases who are apolipoprotein E-ε4 carriers publication-title: Neurobiol Aging – volume: 586 start-page: 417 year: 2020 end-page: 423 ident: bib17 article-title: Negative feedback control of neuronal activity by microglia publication-title: Nature – volume: 17 start-page: 75 year: 2022 ident: bib15 article-title: Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination publication-title: Mol Neurodegener – volume: 12 start-page: 4506 year: 2021 ident: bib46 article-title: Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores publication-title: Nat Commun – volume: 54 start-page: 4 year: 2022 end-page: 17 ident: bib11 article-title: Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies publication-title: Nat Genet – volume: 79 start-page: 652 year: 2022 end-page: 663 ident: bib30 article-title: Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease publication-title: JAMA Neurol – volume: 2 year: 2022 ident: bib48 article-title: Genome-wide risk prediction of common diseases across ancestries in one million people publication-title: Cell Genom – volume: 53 start-page: 1276 year: 2021 end-page: 1282 ident: bib6 article-title: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease publication-title: Nat Genet – volume: 53 start-page: 392 year: 2021 end-page: 402 ident: bib3 article-title: Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes publication-title: Nat Genet – volume: 53 start-page: 1243 year: 2021 end-page: 1249 ident: bib26 article-title: The distribution of common-variant effect sizes publication-title: Nat Genet – volume: 46 start-page: 347 year: 2022 end-page: 371 ident: bib34 article-title: Including diverse and admixed populations in genetic epidemiology research publication-title: Genet Epidemiol – volume: S0006-3223 start-page: 01701 year: 2022 ident: bib49 article-title: Lessons learned from parsing genetic risk for schizophrenia into biological pathways publication-title: Biol Psychiatry – volume: 143 start-page: 2561 year: 2020 end-page: 2575 ident: bib54 article-title: Genetic variants and functional pathways associated with resilience to Alzheimer's disease publication-title: Brain – volume: 11 start-page: 667 year: 2020 ident: bib1 article-title: Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study publication-title: Nat Commun – volume: 54 start-page: 1145 year: 2022 end-page: 1154 ident: bib10 article-title: Genetics of the human microglia regulome refines Alzheimer's disease risk loci publication-title: Nat Genet – volume: 78 start-page: 102 year: 2021 end-page: 113 ident: bib35 article-title: Novel Alzheimer disease risk loci and pathways in African American individuals using the African genome resources panel publication-title: JAMA Neurol – volume: 5 start-page: 336 year: 2022 ident: bib43 article-title: Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels publication-title: Commun Biol – volume: 18 year: 2022 ident: bib24 article-title: Integrated analysis of direct and proxy genome wide association studies highlights polygenicity of Alzheimer's disease outside of the APOE region publication-title: PLoS Genet – volume: 52 start-page: 1346 year: 2020 end-page: 1354 ident: bib51 article-title: Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements publication-title: Nat Genet – volume: 5 start-page: 336 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib43 article-title: Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels publication-title: Commun Biol doi: 10.1038/s42003-022-03287-y – volume: 11 start-page: 667 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib1 article-title: Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study publication-title: Nat Commun doi: 10.1038/s41467-019-14279-8 – volume: 110 start-page: 3513 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib12 article-title: Microglial efferocytosis: diving into the Alzheimer's disease gene pool publication-title: Neuron doi: 10.1016/j.neuron.2022.10.015 – volume: 26 start-page: 309 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib41 article-title: Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging publication-title: Mol Psychiatr doi: 10.1038/s41380-018-0246-7 – volume: 17 start-page: 3 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib29 article-title: Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease publication-title: Mol Neurodegener doi: 10.1186/s13024-021-00505-9 – volume: 19 start-page: 326 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib2 article-title: Interpretation of risk loci from genome-wide association studies of Alzheimer's disease publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30435-1 – volume: 25 start-page: 504 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib32 article-title: Integrating whole-genome sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the human brain publication-title: Nat Neurosci doi: 10.1038/s41593-022-01031-7 – volume: 17 start-page: 1663 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib42 article-title: Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: a genome-wide association study in over 12,000 non-demented participants publication-title: Alzheimers Dementia doi: 10.1002/alz.12333 – volume: 12 start-page: 1610 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib9 article-title: Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes publication-title: Nat Commun doi: 10.1038/s41467-021-21823-y – volume: 54 start-page: 263 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib27 article-title: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data publication-title: Nat Genet doi: 10.1038/s41588-021-00997-7 – volume: 99 start-page: 101.e1 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib47 article-title: Greater effect of polygenic risk score for Alzheimer's disease among younger cases who are apolipoprotein E-ε4 carriers publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2020.09.014 – volume: 53 start-page: 392 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib3 article-title: Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes publication-title: Nat Genet doi: 10.1038/s41588-020-00776-w – volume: 54 start-page: 412 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib5 article-title: New insights into the genetic etiology of Alzheimer's disease and related dementias publication-title: Nat Genet doi: 10.1038/s41588-022-01024-z – volume: 51 start-page: 414 year: 2019 ident: 10.1016/j.ebiom.2023.104511_bib8 article-title: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing publication-title: Nat Genet doi: 10.1038/s41588-019-0358-2 – volume: 54 start-page: 1609 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib52 article-title: A combined polygenic score of 21,293 rare and 22 common variants improves diabetes diagnosis based on hemoglobin A1C levels publication-title: Nat Genet doi: 10.1038/s41588-022-01200-1 – volume: 13 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib31 article-title: APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abc9375 – volume: 12 start-page: 4506 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib46 article-title: Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores publication-title: Nat Commun doi: 10.1038/s41467-021-24082-z – volume: 54 start-page: 1145 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib10 article-title: Genetics of the human microglia regulome refines Alzheimer's disease risk loci publication-title: Nat Genet doi: 10.1038/s41588-022-01149-1 – volume: 4 start-page: fcac125 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib23 article-title: Genome-wide association studies for Alzheimer's disease: bigger is not always better publication-title: Brain Commun doi: 10.1093/braincomms/fcac125 – volume: 23 start-page: 131 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib20 article-title: Open problems in human trait genetics publication-title: Genome Biol doi: 10.1186/s13059-022-02697-9 – volume: 52 start-page: 242 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib33 article-title: The GWAS Diversity Monitor tracks diversity by disease in real time publication-title: Nat Genet doi: 10.1038/s41588-020-0580-y – volume: 9 start-page: 48 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib55 article-title: Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-021-01154-1 – volume: 28 start-page: 1293 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib36 article-title: African ancestry GWAS of dementia in a large military cohort identifies significant risk loci publication-title: Mol Psychiatry doi: 10.1038/s41380-022-01890-3 – volume: 52 start-page: 1346 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib51 article-title: Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements publication-title: Nat Genet doi: 10.1038/s41588-020-00740-8 – volume: 217 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib25 article-title: The genetic architecture of human complex phenotypes is modulated by linkage disequilibrium and heterozygosity publication-title: Genetics doi: 10.1093/genetics/iyaa046 – volume: 12 start-page: 3417 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib4 article-title: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores publication-title: Nat Commun doi: 10.1038/s41467-021-22491-8 – volume: 143 start-page: 2561 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib54 article-title: Genetic variants and functional pathways associated with resilience to Alzheimer's disease publication-title: Brain doi: 10.1093/brain/awaa209 – volume: S0006-3223 start-page: 01701 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib49 article-title: Lessons learned from parsing genetic risk for schizophrenia into biological pathways publication-title: Biol Psychiatry – year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib56 article-title: How to estimate heritability: a guide for genetic epidemiologists publication-title: Int J Epidemiol – volume: 16 start-page: 22 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib14 article-title: TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation publication-title: Mol Neurodegener doi: 10.1186/s13024-021-00436-5 – volume: 53 start-page: 1276 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib6 article-title: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease publication-title: Nat Genet doi: 10.1038/s41588-021-00921-z – volume: 17 start-page: 75 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib15 article-title: Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination publication-title: Mol Neurodegener doi: 10.1186/s13024-022-00577-1 – volume: 54 start-page: 4 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib11 article-title: Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies publication-title: Nat Genet doi: 10.1038/s41588-021-00976-y – volume: 54 start-page: 573 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib53 article-title: Improving polygenic prediction in ancestrally diverse populations publication-title: Nat Genet doi: 10.1038/s41588-022-01054-7 – volume: 185 start-page: 2213 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib18 article-title: Cholesterol and matrisome pathways dysregulated in astrocytes and microglia publication-title: Cell doi: 10.1016/j.cell.2022.05.017 – volume: 4 start-page: fcab308 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib21 article-title: Measuring heritable contributions to Alzheimer's disease: polygenic risk score analysis with twins publication-title: Brain Commun doi: 10.1093/braincomms/fcab308 – volume: 488 start-page: 96 year: 2012 ident: 10.1016/j.ebiom.2023.104511_bib16 article-title: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline publication-title: Nature doi: 10.1038/nature11283 – volume: 586 start-page: 417 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib17 article-title: Negative feedback control of neuronal activity by microglia publication-title: Nature doi: 10.1038/s41586-020-2777-8 – volume: 18 start-page: 1930 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib39 article-title: Identifying differential regulatory control of APOE ϵ4 on African versus European haplotypes as potential therapeutic targets publication-title: Alzheimers Dementia doi: 10.1002/alz.12534 – volume: 53 start-page: 185 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib50 article-title: Genetics of 35 blood and urine biomarkers in the UK Biobank publication-title: Nat Genet doi: 10.1038/s41588-020-00757-z – volume: 15 start-page: 2759 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib45 article-title: Tutorial: a guide to performing polygenic risk score analyses publication-title: Nat Protoc doi: 10.1038/s41596-020-0353-1 – volume: 611 start-page: 1 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib19 article-title: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes publication-title: Nature doi: 10.1038/s41586-022-05439-w – volume: 78 start-page: 102 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib35 article-title: Novel Alzheimer disease risk loci and pathways in African American individuals using the African genome resources panel publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2020.3536 – volume: 79 start-page: 652 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib30 article-title: Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2022.1166 – volume: 11 start-page: 151 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib37 article-title: Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk publication-title: Transl Psychiatry doi: 10.1038/s41398-021-01272-3 – volume: 2 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib48 article-title: Genome-wide risk prediction of common diseases across ancestries in one million people publication-title: Cell Genom – volume: 93 start-page: 29 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib22 article-title: Pervasive downward bias in estimates of liability-scale heritability in GWAS meta-analysis: a simple solution publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2022.05.029 – volume: 51 start-page: 404 year: 2019 ident: 10.1016/j.ebiom.2023.104511_bib7 article-title: Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk publication-title: Nat Genet doi: 10.1038/s41588-018-0311-9 – volume: 46 start-page: 347 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib34 article-title: Including diverse and admixed populations in genetic epidemiology research publication-title: Genet Epidemiol doi: 10.1002/gepi.22492 – volume: 1 start-page: 59 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib28 article-title: Genome-wide association studies publication-title: Nat Rev Methods Primers doi: 10.1038/s43586-021-00056-9 – volume: 76 start-page: 1060 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib44 article-title: An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease publication-title: Alzheimers Dementia – volume: 53 start-page: 1243 year: 2021 ident: 10.1016/j.ebiom.2023.104511_bib26 article-title: The distribution of common-variant effect sizes publication-title: Nat Genet doi: 10.1038/s41588-021-00901-3 – volume: 11 start-page: 506 year: 2020 ident: 10.1016/j.ebiom.2023.104511_bib13 article-title: Microglial corpse clearance: lessons from macrophages publication-title: Front Immunol doi: 10.3389/fimmu.2020.00506 – volume: 18 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib24 article-title: Integrated analysis of direct and proxy genome wide association studies highlights polygenicity of Alzheimer's disease outside of the APOE region publication-title: PLoS Genet doi: 10.1371/journal.pgen.1010208 – volume: 376 start-page: 250 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib38 article-title: Getting genetic ancestry right for science and society publication-title: Science doi: 10.1126/science.abm7530 – volume: 144 start-page: 821 year: 2022 ident: 10.1016/j.ebiom.2023.104511_bib40 article-title: Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers publication-title: Acta Neuropathol doi: 10.1007/s00401-022-02454-z |
| SSID | ssj0001542358 |
| Score | 2.6179159 |
| SecondaryResourceType | review_article |
| Snippet | Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with heritability... SummaryBackgroundAlzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable,... Background: Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder and the most common form of dementia. AD is highly heritable, with... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 104511 |
| SubjectTerms | Advanced Basic Science Alzheimer Disease - pathology Alzheimer's disease Amyloid beta-Peptides - genetics Biomarkers - cerebrospinal fluid Genetic Predisposition to Disease Genome-wide association study Genome-Wide Association Study - methods Humans Internal Medicine Polymorphism, Single Nucleotide Review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDfLS0ZC4kIgfiS2uRVEVSHBBSr1giw_JuqibRY1bVX49XjsZLUB1F64JvFamfnWM5OZ-YaQF8nE-thIVxnjmkoGESojIo4Mc5Ix40KXqyo_fW73D-THw-Zwa9QX1oQVeuAiuDfeCO062dWmM5JH7lrFDLSdqX3kwufTN9m8rWCq9AdL7AHNk-UaXgnTyolyKBd3ATa3v8bR4ZjkbBibmaXM3j-zTn97n38WUW5Zpb1b5OboTtLd8hq3yTXo75DrZcDkz7vkW0IBzVXjcEETVLBjkW7nDui6o7urX0ewPIaTlwMd8zVvab8-hxVd9gMG7wN1faSFfoQWI4hovUcO9j58fb9fjQMVqpACE1YFF7xuZYrpgtJgeHSyhqSaTkDQSiRRx6CE1tGYkOJK1XFgPIBxigFA68R9stOve3hIqI6exeRMtFFJCYF71Xjf8U76poa21gvCJ3naMLKN49CLlZ3Kyr7brASLSrBFCQvyarPoRyHbuPzxd6iozaPIlJ0vJPzYET_2KvwsiJzUbKdm1HR8ph9aXr63-tcyGMYjYLDMDtzW9gsCEPGXYj1Me6YN283K0cspirt6y-cTCm06AzCx43pYnw2WK40T7aWqF-RBQeVGKAI_f7BaLIie4XUmtfmdfnmUecaRnVcyLR_9Dzk_JjfwXUrR0xOyc3pyBk-TP3fqn-W_7m8JFUcb priority: 102 providerName: Directory of Open Access Journals |
| Title | The complex genetic architecture of Alzheimer's disease: novel insights and future directions |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2352396423000762 https://www.clinicalkey.es/playcontent/1-s2.0-S2352396423000762 https://dx.doi.org/10.1016/j.ebiom.2023.104511 https://www.ncbi.nlm.nih.gov/pubmed/36907103 https://www.proquest.com/docview/2786515470 https://pubmed.ncbi.nlm.nih.gov/PMC10024184 https://doaj.org/article/b938af4f09f942d2a6719e6f90bd23b2 |
| Volume | 90 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA_HieCLnN_144gg-GKPNk2bRBA5xeNQThBduBcJSTrxVtb23N7JnX-9maZdr7qcL76Upds0dOaXzkwzMz9CngQTa-uSm1QpU6bcFS5VRY2UYYbnuTLO91mVB--r_Rl_e1gebpCRFXUQYLc2tEM-qdlysXP2_fxlWPAvfudqAdaq7yATOO5ZlljreyWYJoGUBgeDvx_LhjmWhvaEcyVLC1XxsRPR-vtMrFXf1H9itP52Sv_MrbxgrPa2yPXBy6S7ERY3yAY0N8nVyDt5fot8DuCgfTI5nNGAICxkpBe3FGjr6e7i5xHMv8HyaUeHbZzntGl_wILOmw5j-o6apqaxKwmNthFBfJvM9t58er2fDjwLqQvxSp4646yseAj1nJCgWG14BkFjvgAnRWHDTycKKWulXAg3hWeQMwfKiBwAKlPcIZtN28A9QmVt8zr4GFUtOAfHrCit9cxzW2ZQZTIhbJSndkMTcuTCWOgx2-yr7pWgUQk6KiEhz1aDjmMPjssvf4WKWl2KDbT7E-3yix7Wow4PJY3nPlNecVYzU4lcQeVVZmtWWJYQPqpZjzWq4a0abjS_fG6xbhh0I7B1rjumM_0RAYj4CyEg7oaGCavVyMH5iYr795SPRxTq8GrA_R7TQHvaaSYkEt1zkSXkbkTlSigFfhXJsyIhcoLXidSm_zTzo779ODbt5bnk9_-HnB-Qa_gsMRfqIdk8WZ7Co-Dmndjt_vNIOL77ILf7ZfwL6DJRwQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+complex+genetic+architecture+of+Alzheimer%27s+disease%3A+novel+insights+and+future+directions&rft.jtitle=EBioMedicine&rft.au=Shea+J.+Andrews&rft.au=Alan+E.+Renton&rft.au=Brian+Fulton-Howard&rft.au=Anna+Podlesny-Drabiniok&rft.date=2023-04-01&rft.pub=Elsevier&rft.issn=2352-3964&rft.eissn=2352-3964&rft.volume=90&rft.spage=104511&rft_id=info:doi/10.1016%2Fj.ebiom.2023.104511&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b938af4f09f942d2a6719e6f90bd23b2 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23523964%2Fcov200h.gif |